Study Confirms Celiac Disease in School Children of Jordan
I diagnosed myself for gluten intolerance after a lifetime of bizarre, seemingly unrelated afflictions. If my doctors had their way, I would have already undergone neck surgery, still be on 3 different inhalers for asthma, be vomiting daily and having chronic panic attacks. However, since eliminating gluten from my diet in May 2009, I no longer suffer from any of those things. Even with the proof in the pudding (or gluten) my doctors now want me to ingest gluten to test for celiac-no can do.View all articles by Destiny Stone
Celiac.com 02/12/2010 - A recent study to research the predominance of celiac disease in healthy school children in Irbid City, Jordan was conducted using ELISA, a common serological test for the presence of EmA antibodies which are associated with celiac disease.
Serum samples from the children were analyzed for the presence of IgA anti-tissue transglutaminase antibodies (tTG). Samples that tested positive for tTG, were then analyzed for IgA anti-endomysium antibodies (EmA). Positive EmA results indicated the presence of celiac in the children.
Using 868 boys & 1,117 girls ages 5.5 to 9.5, the study measured the positive serology of the children's weight and height, Body Mass Index (BMI) as well as blood samples from the children to determine the prevalence of celiac disease.
The researchers found that 16 of the 1,985 children tested, had positive EmA antibodies, and were also positive for celiac disease. The results further indicated that both boys and girls with positive EmA antibodies also showed significant height reduction compared to children without the presence of the antibodies. However, only boys with positive antibodies showed significant weight reduction.
The study confirmed that celiac disease is widespread among Jordan school children. It also concluded that children with celiac disease are prone to lower height, weight and BMI compared to children with negative EmA antibody results.
As always, Celiac.com welcomes your comments (see below).